FDA Okays First-in-Class Treatment for Obstructive HCM ...Middle East

Medscape - News
Mavacamten is a first-in-class allosteric and reversible inhibitor selective for cardiac my-osin that targets the underlying pathophysiology of obstructive hypertrophic cardiomyo-pathy. FDA Approvals

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Okays First-in-Class Treatment for Obstructive HCM )

Also on site :



Latest News